{"id":"https://openalex.org/W2089714144","doi":"https://doi.org/10.1517/14740338.2013.741585","title":"Examining the safety of PPAR agonists \u2013 current trends and future prospects","display_name":"Examining the safety of PPAR agonists \u2013 current trends and future prospects","alternate_titles":[],"publication_year":2012,"publication_date":"2012-11-08","ids":{"openalex":"https://openalex.org/W2089714144","doi":"https://doi.org/10.1517/14740338.2013.741585","mag":"2089714144","pmid":"https://pubmed.ncbi.nlm.nih.gov/23134541"},"language":"en","primary_location":{"id":"doi:10.1517/14740338.2013.741585","doi":"https://doi.org/10.1517/14740338.2013.741585","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14740338.2013.741585","pdf_url":null,"source":{"id":"https://openalex.org/S20709540","display_name":"Expert Opinion on Drug Safety","issn_l":"1474-0338","issn":["1474-0338","1744-764X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Drug Safety","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2089714144"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111806418","display_name":"Michele Bortolini","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Michele Bortolini","raw_affiliation_strings":["Cardiometabolic Franchise Safety Science Leader, F. Hoffmann-La Roche, Ltd, PDS-Safety Risk Management, 663/2028, CH4070 Basel, Switzerland. michele.bortolini@roche.com","F. Hoffmann-La Roche, Ltd, PDS-Safety Risk Management, 663/2028, CH4070 Basel, Switzerland +41 61 687952; michele.bortolini@roche.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cardiometabolic Franchise Safety Science Leader, F. Hoffmann-La Roche, Ltd, PDS-Safety Risk Management, 663/2028, CH4070 Basel, Switzerland. michele.bortolini@roche.com","institution_ids":["https://openalex.org/I118019719"]},{"raw_affiliation_string":"F. Hoffmann-La Roche, Ltd, PDS-Safety Risk Management, 663/2028, CH4070 Basel, Switzerland +41 61 687952; michele.bortolini@roche.com","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070441005","display_name":"Matthew B. Wright","orcid":"https://orcid.org/0000-0002-0532-3381","observed_orcids":["https://orcid.org/0000-0002-0532-3381"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Matthew B Wright","raw_affiliation_strings":["F. Hoffmann-La Roche, Ltd, Pharma Research & Early Development, DTA Cardiovascular & Metabolism, Grenzacherstrasse 124, CH4070 Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche, Ltd, Pharma Research & Early Development, DTA Cardiovascular & Metabolism, Grenzacherstrasse 124, CH4070 Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004083139","display_name":"Martin Bopst","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Martin Bopst","raw_affiliation_strings":["F. Hoffmann-La Roche, Ltd. Pharma Research & Early Development, Non-Clinical Safety, Grenzacherstrasse 124, CH4070 Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche, Ltd. Pharma Research & Early Development, Non-Clinical Safety, Grenzacherstrasse 124, CH4070 Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5113033858","display_name":"Bogdana Ioana Balas","orcid":"https://orcid.org/0000-0003-0999-6185","observed_orcids":["https://orcid.org/0000-0003-0999-6185"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Bogdana Balas","raw_affiliation_strings":["F. Hoffmann-La Roche, Ltd, PDS-Safety Risk Management, 663/2027, CH4070 Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche, Ltd, PDS-Safety Risk Management, 663/2027, CH4070 Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I118019719"],"apc_list":null,"apc_paid":null,"fwci":0.7165,"has_fulltext":false,"cited_by_count":83,"citation_normalized_percentile":{"value":0.58021104,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"12","issue":"1","first_page":"65","last_page":"79"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11072","display_name":"Peroxisome Proliferator-Activated Receptors","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11072","display_name":"Peroxisome Proliferator-Activated Receptors","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12975","display_name":"Paraoxonase enzyme and polymorphisms","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1308","display_name":"Clinical Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ppar-agonists","display_name":"PPAR agonists","score":0.9190000295639038},{"id":"https://openalex.org/keywords/pparalpha","display_name":"PPAR\u03b1","score":0.7540000081062317},{"id":"https://openalex.org/keywords/ppargamma","display_name":"PPAR\u03b3","score":0.9990000128746033},{"id":"https://openalex.org/keywords/fibrates","display_name":"fibrates","score":0.9359999895095825},{"id":"https://openalex.org/keywords/thiazolidinediones","display_name":"thiazolidinediones","score":0.9679999947547913},{"id":"https://openalex.org/keywords/rosiglitazone","display_name":"rosiglitazone","score":0.8989999890327454},{"id":"https://openalex.org/keywords/pioglitazone","display_name":"pioglitazone","score":0.9990000128746033},{"id":"https://openalex.org/keywords/cardiovascular-safety","display_name":"cardiovascular safety","score":0.6809999942779541},{"id":"https://openalex.org/keywords/bladder-cancer-risk","display_name":"bladder cancer risk","score":0.8870000243186951},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.8920000195503235},{"id":"https://openalex.org/keywords/dyslipidemia","display_name":"dyslipidemia","score":0.9890000224113464},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.6100000143051147},{"id":"https://openalex.org/keywords/cardiometabolic-risk-factors","display_name":"cardiometabolic risk factors","score":0.8240000009536743},{"id":"https://openalex.org/keywords/insulin-resistance","display_name":"insulin resistance","score":0.5680000185966492},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.5799999833106995}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.852981448173523},{"id":"https://openalex.org/C2780152017","wikidata":"https://www.wikidata.org/wiki/Q424771","display_name":"Rosiglitazone","level":3,"score":0.8017315864562988},{"id":"https://openalex.org/C2778384471","wikidata":"https://www.wikidata.org/wiki/Q417765","display_name":"Pioglitazone","level":4,"score":0.7805798053741455},{"id":"https://openalex.org/C2778096610","wikidata":"https://www.wikidata.org/wiki/Q1476525","display_name":"Dyslipidemia","level":3,"score":0.719906747341156},{"id":"https://openalex.org/C2910068830","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 Diabetes Mellitus","level":3,"score":0.5928114056587219},{"id":"https://openalex.org/C7341990","wikidata":"https://www.wikidata.org/wiki/Q10331450","display_name":"PPAR agonist","level":4,"score":0.5624964237213135},{"id":"https://openalex.org/C187345961","wikidata":"https://www.wikidata.org/wiki/Q419629","display_name":"Peroxisome proliferator-activated receptor","level":3,"score":0.5206050872802734},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4714181125164032},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.43935900926589966},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4316941499710083},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.4136834740638733},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.368732213973999},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3103703558444977},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.22027674317359924},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.16470137238502502},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.06571820378303528}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000960","descriptor_name":"Hypolipidemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000960","descriptor_name":"Hypolipidemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000960","descriptor_name":"Hypolipidemic Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D001749","descriptor_name":"Urinary Bladder Neoplasms","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D012307","descriptor_name":"Risk Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018570","descriptor_name":"Risk Assessment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047493","descriptor_name":"PPAR alpha","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D047493","descriptor_name":"PPAR alpha","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true},{"descriptor_ui":"D047495","descriptor_name":"PPAR gamma","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D047495","descriptor_name":"PPAR gamma","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true},{"descriptor_ui":"D050171","descriptor_name":"Dyslipidemias","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D050171","descriptor_name":"Dyslipidemias","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1517/14740338.2013.741585","doi":"https://doi.org/10.1517/14740338.2013.741585","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14740338.2013.741585","pdf_url":null,"source":{"id":"https://openalex.org/S20709540","display_name":"Expert Opinion on Drug Safety","issn_l":"1474-0338","issn":["1474-0338","1744-764X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Drug Safety","raw_type":"journal-article"},{"id":"pmid:23134541","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23134541","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on drug safety","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":131,"referenced_works":["https://openalex.org/W27742310","https://openalex.org/W71678318","https://openalex.org/W1485967434","https://openalex.org/W1596678070","https://openalex.org/W1936322262","https://openalex.org/W1959209560","https://openalex.org/W1968973887","https://openalex.org/W1969161886","https://openalex.org/W1973040217","https://openalex.org/W1976936270","https://openalex.org/W1978960952","https://openalex.org/W1985078263","https://openalex.org/W1990586051","https://openalex.org/W1991786268","https://openalex.org/W1992153775","https://openalex.org/W1992527366","https://openalex.org/W1997030483","https://openalex.org/W1998418707","https://openalex.org/W1999169081","https://openalex.org/W2001174770","https://openalex.org/W2003602721","https://openalex.org/W2005888288","https://openalex.org/W2007582789","https://openalex.org/W2008497553","https://openalex.org/W2013177685","https://openalex.org/W2013297131","https://openalex.org/W2016307947","https://openalex.org/W2019280401","https://openalex.org/W2020720905","https://openalex.org/W2028316975","https://openalex.org/W2028596300","https://openalex.org/W2029811522","https://openalex.org/W2030580012","https://openalex.org/W2031283052","https://openalex.org/W2033817129","https://openalex.org/W2034139682","https://openalex.org/W2034706025","https://openalex.org/W2042689611","https://openalex.org/W2044143483","https://openalex.org/W2045224353","https://openalex.org/W2045497589","https://openalex.org/W2048440354","https://openalex.org/W2048635329","https://openalex.org/W2051006205","https://openalex.org/W2052931002","https://openalex.org/W2052933623","https://openalex.org/W2055769770","https://openalex.org/W2056260385","https://openalex.org/W2060060473","https://openalex.org/W2062255673","https://openalex.org/W2072873519","https://openalex.org/W2077151295","https://openalex.org/W2080424087","https://openalex.org/W2080858771","https://openalex.org/W2081043740","https://openalex.org/W2082432305","https://openalex.org/W2082985492","https://openalex.org/W2085925007","https://openalex.org/W2086602774","https://openalex.org/W2094564105","https://openalex.org/W2096187668","https://openalex.org/W2096210401","https://openalex.org/W2097058003","https://openalex.org/W2097398640","https://openalex.org/W2099929207","https://openalex.org/W2102675827","https://openalex.org/W2103156933","https://openalex.org/W2103393658","https://openalex.org/W2104359225","https://openalex.org/W2105407506","https://openalex.org/W2105719905","https://openalex.org/W2107589145","https://openalex.org/W2108916652","https://openalex.org/W2112394117","https://openalex.org/W2116822087","https://openalex.org/W2118561897","https://openalex.org/W2121264929","https://openalex.org/W2121914083","https://openalex.org/W2127125241","https://openalex.org/W2128080366","https://openalex.org/W2130957039","https://openalex.org/W2131490500","https://openalex.org/W2131964379","https://openalex.org/W2132600168","https://openalex.org/W2133377772","https://openalex.org/W2134382958","https://openalex.org/W2134489589","https://openalex.org/W2135031161","https://openalex.org/W2135401506","https://openalex.org/W2135729475","https://openalex.org/W2137914533","https://openalex.org/W2138011449","https://openalex.org/W2139341329","https://openalex.org/W2143199040","https://openalex.org/W2145777529","https://openalex.org/W2152710192","https://openalex.org/W2153776436","https://openalex.org/W2154580171","https://openalex.org/W2155258805","https://openalex.org/W2156116850","https://openalex.org/W2156994876","https://openalex.org/W2158323596","https://openalex.org/W2159969745","https://openalex.org/W2160362502","https://openalex.org/W2161241963","https://openalex.org/W2161583137","https://openalex.org/W2162051951","https://openalex.org/W2163007960","https://openalex.org/W2164324917","https://openalex.org/W2165089183","https://openalex.org/W2165815833","https://openalex.org/W2166179667","https://openalex.org/W2167788046","https://openalex.org/W2169126205","https://openalex.org/W2169881063","https://openalex.org/W2171981572","https://openalex.org/W2172203327","https://openalex.org/W2176792792","https://openalex.org/W2198678228","https://openalex.org/W2313240267","https://openalex.org/W2322346398","https://openalex.org/W2328529137","https://openalex.org/W2341665659","https://openalex.org/W2417386509","https://openalex.org/W2440811944","https://openalex.org/W2615845755","https://openalex.org/W4211121381","https://openalex.org/W4238251256","https://openalex.org/W4240449862","https://openalex.org/W4249825849","https://openalex.org/W4406060562"],"related_works":["https://openalex.org/W2002412565","https://openalex.org/W1977041568","https://openalex.org/W2044431460","https://openalex.org/W2100641739","https://openalex.org/W1991113982","https://openalex.org/W2142642388","https://openalex.org/W2057899697","https://openalex.org/W2062551263","https://openalex.org/W2144040195"],"abstract_inverted_index":{"INTRODUCTION:":[0],"The":[1,73,104],"peroxisome":[2],"proliferator-activated":[3],"receptor":[4],"(PPAR)-\u03b1":[5],"and":[6,10,17,42,50,53,130,142,170],"-\u03b3":[7,131,171],"agonists,":[8],"fibrates":[9],"glitazones,":[11],"are":[12,63],"effective":[13],"treatments":[14],"for":[15,80,97,121,125],"dyslipidemia":[16],"type":[18,99],"2":[19,100],"diabetes":[20,101],"mellitus,":[21],"respectively,":[22],"but":[23],"exhibit":[24],"class-related,":[25],"as":[26,28,153],"well":[27],"compound-specific":[29,51],"safety":[30,92,123],"characteristics.":[31],"AREAS":[32],"COVERED:":[33],"This":[34],"article":[35],"reviews":[36],"the":[37,108,119,163],"profiles":[38],"of":[39,90,112],"PPAR-\u03b1,":[40],"PPAR-\u03b3,":[41],"dual":[43],"PPAR-\u03b1/\u03b3":[44],"agonists":[45],"with":[46,115],"regard":[47],"to":[48,66,85],"class-related":[49],"efficacy":[52,177],"adverse":[54],"effects.":[55,182],"We":[56],"explore":[57],"how":[58],"learnings":[59],"from":[60],"first-generation":[61],"drugs":[62],"being":[64],"applied":[65],"develop":[67],"safer":[68],"PPAR-targeted":[69,159],"therapies.":[70],"EXPERT":[71],"OPINION:":[72],"finding":[74],"that":[75,161],"rosiglitazone":[76],"may":[77,117],"increase":[78],"risk":[79,111,135],"cardiovascular":[81,91],"events":[82],"has":[83,151],"led":[84],"regulatory":[86],"guidelines":[87],"requiring":[88],"demonstration":[89],"in":[93,144,175],"appropriate":[94],"outcome":[95],"trials":[96],"new":[98,126],"mellitus":[102],"drugs.":[103,127],"emerging":[105],"data":[106],"on":[107],"possibly":[109],"increased":[110],"bladder":[113],"cancer":[114],"pioglitazone":[116],"prompt":[118],"need":[120],"post-approval":[122],"studies":[124],"Since":[128],"PPAR-\u03b1":[129,169],"affect":[132],"key":[133],"cardiometabolic":[134],"factors":[136],"(diabetic":[137],"dyslipidemia,":[138],"insulin":[139],"resistance,":[140],"hyperglycemia,":[141],"inflammation)":[143],"a":[145,154],"complementary":[146],"fashion,":[147],"combining":[148],"their":[149],"benefits":[150],"emerged":[152],"particularly":[155],"attractive":[156],"option.":[157],"New":[158],"therapies":[160],"balance":[162],"relative":[164],"potency":[165],"and/or":[166],"activity":[167],"toward":[168],"have":[172],"shown":[173],"promise":[174],"retaining":[176],"while":[178],"reducing":[179],"potential":[180],"side":[181]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2089714144","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":8},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":8},{"year":2017,"cited_by_count":5},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":7},{"year":2014,"cited_by_count":13},{"year":2013,"cited_by_count":8}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
